Invesco Ltd. Pacira Bio Sciences, Inc. Transaction History

Invesco Ltd.

$499 Billion
Q3 2024

A detailed history of Invesco Ltd. transactions in Pacira Bio Sciences, Inc. stock. As of the latest transaction made, Invesco Ltd. holds 924,145 shares of PCRX stock, worth $17.5 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

924,145

Previous 548,607 68.45%

Holding current value

$17.5 Million

Previous $15.7 Million 11.33%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$11.7 - $28.46 $4.39 Million - $10.7 Million	375,538 Added 68.45%	924,145 $13.9 Million
Q2 2024 Aug 13, 2024	SELL	$25.5 - $31.51 $52,326 - $64,658	-2,052 Reduced 0.37%	548,607 $15.7 Million
Q1 2024 May 14, 2024	BUY	$27.7 - $35.48 $1.97 Million - $2.52 Million	71,065 Added 14.82%	550,659 $16.1 Million
Q4 2023 Feb 12, 2024	SELL	$26.32 - $34.31 $11.5 Million - $14.9 Million	-435,113 Reduced 47.57%	479,594 $16.2 Million
Q3 2023 Nov 13, 2023	SELL	$30.68 - $40.09 $14.4 Million - $18.8 Million	-470,177 Reduced 33.95%	914,707 $28.1 Million
Q2 2023 Aug 11, 2023	SELL	$36.12 - $47.5 $491,304 - $646,095	-13,602 Reduced 0.97%	1,384,884 $55.5 Million
Q1 2023 May 12, 2023	BUY	$35.53 - $43.38 $1.34 Million - $1.64 Million	37,853 Added 2.78%	1,398,486 $57.1 Million
Q4 2022 Feb 13, 2023	BUY	$38.19 - $57.45 $8.31 Million - $12.5 Million	217,664 Added 19.04%	1,360,633 $52.5 Million
Q3 2022 Nov 14, 2022	BUY	$51.24 - $58.89 $2.78 Million - $3.19 Million	54,228 Added 4.98%	1,142,969 $60.8 Million
Q2 2022 Aug 15, 2022	BUY	$51.49 - $81.64 $36.9 Million - $58.5 Million	716,018 Added 192.1%	1,088,741 $63.5 Million
Q1 2022 May 16, 2022	SELL	$60.03 - $76.49 $5.92 Million - $7.55 Million	-98,643 Reduced 20.93%	372,723 $28.4 Million
Q4 2021 Feb 14, 2022	SELL	$47.97 - $62.21 $3.27 Million - $4.24 Million	-68,138 Reduced 12.63%	471,366 $28.4 Million
Q3 2021 Nov 15, 2021	BUY	$54.64 - $61.3 $4.67 Million - $5.24 Million	85,413 Added 18.81%	539,504 $30.2 Million
Q2 2021 Aug 17, 2021	SELL	$59.18 - $69.99 $5.95 Million - $7.04 Million	-100,599 Reduced 18.14%	454,091 $27.6 Million
Q1 2021 May 17, 2021	SELL	$59.31 - $78.82 $2.96 Million - $3.93 Million	-49,865 Reduced 8.25%	554,690 $38.9 Million
Q4 2020 Feb 16, 2021	SELL	$50.47 - $66.26 $24,276 - $31,871	-481 Reduced 0.08%	604,555 $36.2 Million
Q3 2020 Nov 16, 2020	SELL	$51.97 - $63.0 $3.48 Million - $4.22 Million	-67,008 Reduced 9.97%	605,036 $36.4 Million
Q2 2020 Aug 14, 2020	BUY	$30.8 - $52.47 $6.87 Million - $11.7 Million	223,137 Added 49.71%	672,044 $35.3 Million
Q1 2020 May 15, 2020	SELL	$28.4 - $50.7 $4.59 Million - $8.19 Million	-161,445 Reduced 26.45%	448,907 $15.1 Million
Q4 2019 Feb 14, 2020	BUY	$36.31 - $46.83 $13.8 Million - $17.8 Million	380,422 Added 165.45%	610,352 $27.6 Million
Q3 2019 Nov 14, 2019	SELL	$35.66 - $44.99 $2.88 Million - $3.64 Million	-80,849 Reduced 26.01%	229,930 $8.75 Million
Q2 2019 Aug 14, 2019	SELL	$36.57 - $47.97 $3.16 Million - $4.14 Million	-86,362 Reduced 21.75%	310,779 $13.5 Million
Q1 2019 May 15, 2019	BUY	$36.47 - $42.17 $883,485 - $1.02 Million	24,225 Added 6.5%	397,141 $15.1 Million
Q4 2018 Feb 14, 2019	BUY	$41.31 - $52.16 $15.4 Million - $19.5 Million	372,916 New	372,916 $16 Million

Others Institutions Holding PCRX

# of Institutions

263

Shares Held

50.4M

Call Options Held

429K

Put Options Held

391K

View Full List

About Pacira BioSciences, Inc.

Ticker PCRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 45,824,200
Market Cap $870M
Description
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...

More about PCRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Invesco Ltd. with notifications on news.

Account